VetStem Biopharma Secures FDA Approval of First Human IND
VetStem Biopharma, a veterinary and human regenerative medicine CRO, used its extensive experience, FDA master files, and database of veterinary stem cell therapy to secure FDA approval of a human IND for stem cell therapy in patients with osteoarthritis. VetStem made the application to FDA on behalf of its subsidiary, Personalized Stem Cells, Inc.
